These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11835885)

  • 1. [False negative and false positive results of tumor markers: their limitation in clinical practice. Clinical applications of CA-125].
    Jiménez Lacave A; Allende Monclús M
    Rev Clin Esp; 2001 Dec; 201(12):715-7. PubMed ID: 11835885
    [No Abstract]   [Full Text] [Related]  

  • 2. The value of 18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening.
    Shen YY; Su CT; Chen GJ; Chen YK; Liao AC; Tsai FS
    Neoplasma; 2003; 50(3):217-21. PubMed ID: 12937856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of tumor markers in serum. Pitfalls and good practice.
    Basuyau JP; Leroy M; Brunelle P
    Clin Chem Lab Med; 2001 Dec; 39(12):1227-33. PubMed ID: 11798082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors.
    Høgdall CK; Mogensen O; Tabor A; Mogensen B; Jakobsen AK; Nørgaard-Pedersen B; Larsen SO; Clemmensen I
    Gynecol Oncol; 1995 Jan; 56(1):22-8. PubMed ID: 7821842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of imprint cytology in tumor diagnosis: a retrospective study of 522 cases in northern China.
    Lee TK
    Acta Cytol; 1982; 26(2):169-71. PubMed ID: 6952718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(6B):2309-14. PubMed ID: 1295478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How CA 125 is used in routine clinical practice.
    Petignat P; Joris F; Obrist R
    Eur J Cancer; 2000 Oct; 36(15):1933-7. PubMed ID: 11000573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study of Tc-99m MIBI in the differential diagnosis of pelvic masses in female patients.
    Tian J; Zhang J; Jiao L; Li Y; Cao L
    Clin Nucl Med; 2000 Aug; 25(8):614-8. PubMed ID: 10944017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CA 125 as a screening test for ovarian cancer.
    Hakama M; Stenman UH; Knekt P; Järvisalo J; Hakulinen T; Maatela J; Aromaa A
    J Med Screen; 1996; 3(1):40-2. PubMed ID: 8861050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence?
    Friedrich MG; Hellstern A; Toma MI; Hammerer P; Huland H
    Eur Urol; 2003 Feb; 43(2):146-50; discussion 150-1. PubMed ID: 12565772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of preoperative criteria used to predict lymph node metastasis in endometrial cancer.
    Han SS; Lee SH; Kim DH; Kim JW; Park NH; Kang SB; Song YS
    Acta Obstet Gynecol Scand; 2010; 89(2):168-74. PubMed ID: 19916890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated serum CA-125 levels: hepatitis or ascites?
    Sevinc A; Buyukberber S; Sari R
    Gynecol Oncol; 2000 Jan; 76(1):141-2. PubMed ID: 10620461
    [No Abstract]   [Full Text] [Related]  

  • 13. [The concentration of carcinoembryonic antigen and carbohydrate antigen Ca-19-9 in the blood serum in cancerous diseases of the gastrointestinal tract].
    Mit'kov VV; Ogneva TV; Goriaĭnova II; Milanov S; Milkov V
    Med Radiol (Mosk); 1989 Nov; 34(11):22-4. PubMed ID: 2586258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. False positive and false negative reactions in HLA B-27 antigen testing.
    Larsen AE
    Transfusion; 1979; 19(2):219-21. PubMed ID: 432934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CA-125: a biomarker put to the test.
    Schmidt C
    J Natl Cancer Inst; 2011 Sep; 103(17):1290-1. PubMed ID: 21852262
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
    Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genitourinary tuberculosis, CA-125 and tuberculin anergy in disseminated tuberculosis.
    Jolobe O
    QJM; 2015 Dec; 108(12):993. PubMed ID: 25972350
    [No Abstract]   [Full Text] [Related]  

  • 18. [Detection of early prostatic cancer in mass screening program].
    Ohe H
    Hinyokika Kiyo; 1991 Aug; 37(8):785-8. PubMed ID: 1720271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating Prognostic Markers Using Relative Utility Curves and Test Tradeoffs.
    Baker SG; Kramer BS
    J Clin Oncol; 2015 Aug; 33(23):2578-80. PubMed ID: 26124476
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of immunoscintigraphy with monoclonal antibodies in assays of hormones and tumour markers.
    Janssen JA; Blankestijn PJ; Docter R; Blijenberg BG; Splinter TA; van Toor H; Schalekamp MA; Lamberts SW; Krenning EP
    BMJ; 1989 Jun; 298(6686):1511-3. PubMed ID: 2503094
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.